Denis Moro-Sibilot

List of Publications by Year
in descending order

90 papers	10,796 citations	87723 38 h-index	42291 92 g-index
93 all docs	93 docs citations	93 times ranked	11626 citing authors

#	Article	IF	Citations
1	Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	13.9	3,181
2	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2016, 387, 1405-1414.	6.3	753
3	Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. Journal of Clinical Oncology, 2013, 31, 1997-2003.	0.8	572
4	Alectinib in Crizotinib-Refractory ALK-Rearranged Nonâ€“Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 2016, 34, 661-668.	0.8	548
5	Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2002, 20, 247-253.	0.8	535
6	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet, The, 2011, 378, 1079-1088.	6.3	521
7	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
8	Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers. Science Translational Medicine, 2013, 5, 186ra66.	5.8	392
9	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncology, The, 2019, 20, 239-253.	5.1	342
10	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of AlectinibÂinÂUntreated ALK-Positive Advanced Nonâ€“Small CellÂLung Cancer in the Global Phase III ALEX Study. Journal of Thoracic Oncology, 2019, 14, 1233-1243.	0.5	324
11	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	5.8	254
12	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	7.7	238
13	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	15.2	225
14	Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study. Journal of Thoracic Oncology, 2012, 7, 348-354.	0.5	197
15	Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 2167-2172.	0.8	170
16	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget, 2017, 8, 21903-21917.	0.8	140
17	On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer, 2014, 83, 168-173.	0.9	113
18	A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. Journal of Thoracic Oncology, 2019, 14, 130-134.	0.5	92

#	Article	IF	Citations
19	Use of Intensive Care in Patients With Nonresectable Lung Cancer. Chest, 2011, 139, 101-108.	0.4	84
20	Endovascular Treatment of Malignant Superior Vena Cava Syndrome: Results and Predictive Factors of Clinical Efficacy. CardioVascular and Interventional Radiology, 2013, 36, 140-149.	0.9	83
21	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Nonâ€“Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics, 2012, 11, 1203-1213.	1.9	77
22	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. European Respiratory Journal, 2015, 45, 1403-1414.	3.1	66
23	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer, 2015, 88, 215-222.	0.9	58
24	Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer, 2015, 90, 427-432.	0.9	57
25	Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib. Journal of Thoracic Oncology, 2012, 7, e1-e2.	0.5	56
26	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Journal of Thoracic Oncology, 2017, 12, 963-973.	0.5	56
27	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clinical Cancer Research, 2012, 18, 2976-2986.	3.2	52
28	IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype. Journal of Thoracic Oncology, 2009, 4, 1126-1135.	0.5	51
29	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. Journal of Thoracic Oncology, 2010, 5, 491-496.	0.5	51
30	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575.	1.1	49
31	c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. Journal of Thoracic Oncology, 2018, 13, 1962-1967.	0.5	48
32	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9043-9043.	0.8	45
33	Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: Influence of ATS/ERS/IASLC guidelines. Lung Cancer, 2013, 82, 69-75.	0.9	44
34	Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity. Clinical Cancer Research, 2014, 20, 5777-5786.	3.2	44
35	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer, 2018, 116, 15-24.	0.9	44
36	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous nonâ€“small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European Journal of Cancer, 2020, 131, 27-36.	1.3	44

#	Article	IF	Citations
37	Insulinâ€like growth factorâ€1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Journal of Pathology, 2011, 225, 83-95.	2.1	43
38	Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. European Journal of Cancer, 2016, 52, 120-128.	1.3	42
39	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer, 2010, 70, 301-307.	0.9	40
40	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer, 2015, 87, 89-95.	0.9	40
41	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial. Journal of Clinical Oncology, 2022, 40, 719-728.	0.8	37
42	Prognostic Impact of Paraneoplastic Cushingâ€™s Syndrome in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 497-505.	0.5	34
43	Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. Lung Cancer, 2010, 69, 180-186.	0.9	32
44	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€“Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
45	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Medicine, 2015, 41, 164-165.	3.9	28
46	Selection criteria for intensive care unit referral of lung cancer patients: a pilot study. European Respiratory Journal, 2015, 45, 491-500.	3.1	26
47	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. Journal of Thoracic Oncology, 2020, 15, 120-124.	0.5	24
48	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3112.	1.7	23
49	Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017. Lung Cancer, 2019, 131, 122-127.	0.9	22
50	Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients. Lung Cancer, 2012, 78, 112-120.	0.9	21
51	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. British Journal of Cancer, 2019, 120, 387-397.	2.9	19
52	Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME). Lung Cancer, 2012, 78, 263-269.	0.9	18
53	Association between lung cancer somatic mutations and occupational exposure in never-smokers. European Respiratory Journal, 2017, 50, 1700716.	3.1	16
54	Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European Respiratory Journal, 2018, 51, 1701467.	3.1	16

#	Article	IF	Citations
55	MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. Oncotarget, 2017, 8, 4313-4329.	0.8	16
56	Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Current Medical Research and Opinion, 2010, 26, 2661-2672.	0.9	15
57	Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer, 2014, 83, 182-188.	0.9	15
58	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. Lung Cancer, 2016, 92, 35-40.	0.9	15
59	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research, 2019, 25, 5759-5765.	3.2	13
60	Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial. Clinical Cancer Research, 2020, 26, 3172-3181.	3.2	13
61	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. Current Medical Research and Opinion, 2020, 36, 1667-1675.	0.9	11
62	Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. European Respiratory Journal, 2014, 43, 240-249.	3.1	10
63	Are Clinical Guidelines Applied in Routine Daily Practice? A French Regional Survey of Physicians' Clinical Practices in Lung Cancer Management (EPOTRA). Clinical Lung Cancer, 2011, 12, 298-306.	1.1	9
64	Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial. Journal of Thoracic Oncology, 2012, 7, 1423-1431.	0.5	9
65	Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study. Current Medical Research and Opinion, 2012, 28, 1253-1262.	0.9	9
66	ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. Expert Review of Anticancer Therapy, 2015, 15, 225-233.	1.1	9
67	Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing. Lung Cancer, 2020, 140, 93-98.	0.9	9
68	First-Line Afatinib plus Cetuximab for EGFR-Mutant Nonâ€“Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study. Clinical Cancer Research, 2021, 27, 4168-4176.	3.2	9
69	Real-life experience of ceritinib in crizotinib-pretreated ALK⁺ advanced non-small cell lung cancer patients. ERJ Open Research, 2018, 4, 00058-2017.	1.1	8
70	Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSÃ© Program.. Journal of Clinical Oncology, 2018, 36, 2504-2504.	0.8	8
71	Pratique professionnelle et accessibilitÃ© aux Ã©quipements en oncologie thoracique. RÃ©sultats dâ€™une enquÃªte de pratique en rÃ©gion RhÃ´ne-Alpes. Bulletin Du Cancer, 2011, 98, 613-623.	0.6	7
72	Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301). Journal of Geriatric Oncology, 2015, 6, 233-240.	0.5	7

#	Article	IF	Citations
73	Erlotinibversuscarboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. European Respiratory Journal, 2015, 46, 1440-1450.	3.1	7
74	Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.. Journal of Clinical Oncology, 2018, 36, 9097-9097.	0.8	5
75	Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).. Journal of Clinical Oncology, 2019, 37, 9079-9079.	0.8	5
76	Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced nonâ€“small cell lung cancer: IFCT-1201 MODEL trial. European Journal of Cancer, 2020, 138, 193-201.	1.3	4
77	Comprehensive Genome Profiling in Patients With Metastatic Nonâ€“Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. Clinical Cancer Research, 2022, 28, 4018-4026.	3.2	4
78	The TAILOR study: To agree or to disagree?. Lung Cancer, 2014, 84, 315-316.	0.9	3
79	Prise en charge oncologique du patient opÃ©rÃ©: chimiothÃ©rapie adjuvante, surveillance, traitement des rechutes. Oncologie, 2008, 10, 525-528.	0.2	2
80	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. Future Oncology, 2019, 15, 2139-2149.	1.1	2
81	Precision medicine at its best: Prolonged survival in a child presenting a secondary mesothelioma treated with crizotinib. Pediatric Blood and Cancer, 2021, 68, e28666.	0.8	2
82	Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. Journal of Clinical Oncology, 2018, 36, 8505-8505.	0.8	2
83	Detection of ROS1 translocations in triple-negative lung adenocarcinomas.. Journal of Clinical Oncology, 2013, 31, 8099-8099.	0.8	2
84	P3-071: Respiratory symptoms improvement in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib: Quality of Life analysis of the IFCT-0401 trial. Journal of Thoracic Oncology, 2007, 2, S708.	0.5	1
85	Pathologie avancÃ©e et dÃ©faillances dâ€™organesÂ: outil dâ€™aide Ã la dÃ©cision. Medecine Palliative, 2014, 13, 150-154.	0.0	1
86	Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.. Journal of Clinical Oncology, 2015, 33, 7510-7510.	0.8	1
87	Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017.. Journal of Clinical Oncology, 2018, 36, e20572-e20572.	0.8	1
88	A defect of amphiregulin release predicted longer survival independently of <scp>YAP</scp> expression in patients with pleural mesothelioma in the <scp>IFCT</scp> â€0701 <scp>MAPS</scp> phase 3 trial. International Journal of Cancer, 2022, 150, 1889-1904.	2.3	1
89	Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases. Frontiers in Oncology, 2022, 12, 787080.	1.3	1
90	P3-118: IFCT-0301 randomized phase II trial of gefitinib, gemcitabine or docetaxel in Performance Status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients: analysis of the clinical impact of comorbidities and tumour burden. Journal of Thoracic Oncology, 2007, 2, S729.	0.5	0